United States securities and exchange commission logo





                              September 16, 2020

       David H. Mack, Ph.D.
       President and Chief Executive Officer
       PMV Pharmaceuticals, Inc.
       8 Clarke Drive, Suite 3
       Cranbury, NJ 08512

                                                        Re: PMV
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed September 4,
2020
                                                            File No. 333-248627

       Dear Dr. Mack:

               We have reviewed your amended registration statement and have
the following
       comment. In some of our comments, we may ask you to provide us with
information so we may
       better understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Registration Statement on Form S-1

       Prospectus Summary, page 1

   1.                                                   We note your response
to prior comment 2 that you have revised your disclosure on page
                                                        2 to disclose that the
FDA will require post-approval trials to confirm clinical benefit.
                                                        However, we note that
you also refer to a pivotal Phase 1/2 trial on page 1, stating that the
                                                        FDA "could" ask for
additional trials. Please delete the last two sentences on page 1, as
                                                        you already have a
discussion about your belief of a potential pivotal trial on page 2. In
                                                        addition, to the extent
true, please also add on page 2 that you have not had any
                                                        discussions with the
FDA regarding the trial being a pivotal trial.

              We remind you that the company and its management are responsible
for the accuracy
       and adequacy of their disclosures, notwithstanding any review, comments,
action or absence of
 David H. Mack, Ph.D.
PMV Pharmaceuticals, Inc.
September 16, 2020
Page 2

action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Ameen Hamady at 202-551-3891 or Kevin Kuhar at
202-551-3662 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Deanna Virginio at 202-551-4530 or Dorrie Yale at 202-551-8776 with any
other
questions.



                                                           Sincerely,
FirstName LastNameDavid H. Mack, Ph.D.
                                                           Division of
Corporation Finance
Comapany NamePMV Pharmaceuticals, Inc.
                                                           Office of Life
Sciences
September 16, 2020 Page 2
cc:       Megan J. Baier, Esq.
FirstName LastName